{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T07:21:17Z","timestamp":1773127277508,"version":"3.50.1"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>the present study aims to evaluate body composition and its relationship with hormonal control in acromegaly, also comparing the performance of Bioelectrical impedance analysis (BIA), a more accessible method, with dual X-ray absorptiometry (DXA), technology frequently used in current studies. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>we studied 28 patients (78% female) of whom 13 with active disease, mean age was 52.11 \u00b1 12.53 years; 64% had high blood pressure (HBP) and 50% had type 2 diabetes (T2D).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Although patients with controlled disease had lower serum GH (1.2 \u00b1 1.68\u00b5g\/L <jats:italic>vs<\/jats:italic> 6.61 \u00b1 6.40\u00b5g\/L, p=0.001) and IGF-1 (158.89 \u00b1 54.53ng\/mL and 503.31 \u00b1 253.25ng\/mL, p&amp;lt;0.001), they did not differ in body composition: percentage of fat mass: 36.13 \u00b1 11.84% <jats:italic>vs<\/jats:italic> 37.73 \u00b1 8.76%, p=0.691 for BIA and 37.10 \u00b1 10.21% <jats:italic>vs<\/jats:italic> 37.89 \u00b1 7.32%, p=0.819 for DXA; muscle mass parameters, BIA: FFMI 18.68 \u00b1 2.38kg\/m<jats:sup>2<\/jats:sup><jats:italic>vs<\/jats:italic> 19.14 \u00b1 1.59kg\/m<jats:sup>2<\/jats:sup>, p=0.560; SMI 10.17 \u00b1 1.39kg\/m<jats:sup>2<\/jats:sup><jats:italic>vs<\/jats:italic> 10.53 \u00b1 1.01kg\/m<jats:sup>2<\/jats:sup>, p=0.438; DXA: Baumgartner 7.99 \u00b1 1.43kg\/m<jats:sup>2<\/jats:sup><jats:italic>vs<\/jats:italic> 8.02 \u00b1 1.24kg\/m<jats:sup>2<\/jats:sup>, p=0.947, respectively for controlled and active disease. Patients with controlled acromegaly had lower fasting glucose (110.33 \u00b1 55.48mg\/dL <jats:italic>vs<\/jats:italic> 129.77 \u00b1 40.17mg\/dL, p=0.033) and were less likely to have persistent T2D (28.6 vs 71.4%, p=0.008) and HBP (38.9 vs 61.1%, p=0.049). There were strong positive correlations between BIA and DXA for fat mass (r=0.929, p&amp;lt;0.001) and muscle mass parameters: SMI X Baumgartner: r=0.890, p&amp;lt;0.001; and FFMI X Baumgartner: r=0.868, p&amp;lt;0.001.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>our data showed similar results in body composition assessment by BIA and DXA, with good correlation between the methods, regardless of the hormonal status of acromegaly. Furthermore, in patients with adequate hormonal control, there was preservation of muscle mass and a lower prevalence of metabolic comorbidities, such as T2D and HBP.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2022.866099","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T06:21:17Z","timestamp":1652854877000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Body Composition in Acromegaly According to Disease Activity \u2013 Performance of Dual X-Ray Absorptiometry and Multifrequency Bioelectrical Impedance Analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Aline Alves","family":"Lopes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciano","family":"Albuquerque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayara","family":"Fontes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniella","family":"Rego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Bandeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-16-0117","article-title":"Acromegaly Incidence, Prevalence, Complications and Long-Term Prognosis: A Nationwide Cohort Study","volume":"175","author":"Dal","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-019-0071-6","article-title":"Acromegaly","volume":"5","author":"Colao","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00509","article-title":"Insulin Resistance in Patients With Acromegaly","volume":"10","author":"Vila","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-17-0253","article-title":"Acromegaly at Diagnosis in 3173 Patients From the Li\u00e8ge Acromegaly Survey (Las) Database","volume":"24","author":"Petrossians","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2700","article-title":"Endocrine Society. Acromegaly: An Endocrine Society Clinical Practice Guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","first-page":"dgz096","DOI":"10.1210\/clinem\/dgz096","article-title":"A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update","volume":"105","author":"Giustina","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-013-0471-7","article-title":"Prevalence and Risk Factors of Impaired Glucose Tolerance and Diabetes Mellitus at Diagnosis of Acromegaly: A Study in 148 Patients","volume":"17","author":"Alexopoulou","year":"2014","journal-title":"Pituitary"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1210\/er.2018-00115","article-title":"Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update","volume":"40","author":"Gadelha","year":"2019","journal-title":"Endocr Rev"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1210\/er.2008-0027","article-title":"Effects of Growth Hormone on Glucose, Lipid, and Protein Metabolism in Human Subjects","volume":"30","author":"Moller","year":"2009","journal-title":"Endocr Rev"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-020-09588-z","article-title":"Multidisciplinary Management of Acromegaly: A Consensus","volume":"21","author":"Giustina","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-018-0058-5","article-title":"A Consensus Statement on Acromegaly Therapeutic Outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"R89","DOI":"10.1530\/EJE-17-1006","article-title":"Management of Endocrine Disease: Personalized Medicine in the Treatment of Acromegaly","volume":"178","author":"Kasuki","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-008-0104-8","article-title":"Alterations in Body Composition in Acromegaly","volume":"12","author":"Katznelson","year":"2009","journal-title":"Pituitary"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2012.04361.x","article-title":"Effects of Growth Hormone Deficiency on Body Composition and Biomarkers of Cardiovascular Risk After Definitive Therapy for Acromegaly","volume":"77","author":"Lin","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-015-0657-2","article-title":"IGF-1 Levels Across the Spectrum of Normal to Elevated in Acromegaly: Relationship to Insulin Sensitivity, Markers of Cardiovascular Risk and Body Composition","volume":"18","author":"Reid","year":"2015","journal-title":"Pituitary"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1917","article-title":"Adipose Tissue Redistribution and Ectopic Lipid Deposition in Active Acromegaly and Effects of Surgical Treatment","volume":"100","author":"Reyes-Vidal","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B17","doi-asserted-by":"publisher","first-page":"bvab004","DOI":"10.1210\/jendso\/bvab004","article-title":"Body Composition Changes With Long-term Pegvisomant Therapy of Acromegaly","volume":"5","author":"Kuker","year":"2021","journal-title":"J Endocr Soc"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4125013","DOI":"10.1155\/2018\/4125013","article-title":"Pre- and Postoperative Body Composition and Metabolic Characteristics in Patients With Acromegaly: A Prospective Study","volume":"2018","author":"Guo","year":"2018","journal-title":"Int J Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2000.00910.x","article-title":"Administration of Recombinant Human Growth Hormone on Alternate Days Is Sufficient to Increase Whole Body Protein Synthesis and Lipolysis in Growth Hormone Deficient Adults","volume":"52","author":"Lucidi","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2020.02.009","article-title":"Growth Hormone and Obesity","volume":"49","author":"Hjelholt","year":"2020","journal-title":"Endocrinol Metab Clinics"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-0026","article-title":"Skeletal Muscle Mass in Acromegaly Assessed by Magnetic Resonance Imaging and Dual-Photon X-Ray Absorptiometry","volume":"94","author":"Freda","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B22","doi-asserted-by":"publisher","first-page":"115583","DOI":"10.1016\/j.bone.2020.115583","article-title":"Impaired Physical Function and Evaluation of Quality of Life in Normocalcemic and Hypercalcemic Primary Hyperparathyroidism","volume":"141","author":"Voss","year":"2020","journal-title":"Bone"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-020-04625-x","article-title":"Body Composition, Serum Sclerostin and Physical Function After Bariatric Surgery: Performance of Dual-Energy X-Ray Absorptiometry and Multifrequency Bioelectrical Impedance Analysis","volume":"30","author":"de Oliveira","year":"2020","journal-title":"Obes Surg"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00325","article-title":"Persistence of Diabetes and Hypertension After Multimodal Treatment of Acromegaly","volume":"103","author":"Gonzalez","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2019.08.008","article-title":"Hypertension and Acromegaly","volume":"48","author":"Puglisi","year":"2019","journal-title":"Endocrinol Metab Clinics"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2468","article-title":"A Structural and Functional Acromegaly Classification","volume":"100","author":"Cuevas-Ramos","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1500763","article-title":"Clinical, Hormonal and Magnetic Resonance Imaging (MRI) Predictors of Transsphenoidal Surgery Outcome in Acromegaly","volume":"150","author":"Bourdelot","year":"2004","journal-title":"Eur J Endocrinol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.866099\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T06:21:19Z","timestamp":1652854879000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.866099\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,18]]},"references-count":27,"alternative-id":["10.3389\/fendo.2022.866099"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.866099","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,18]]},"article-number":"866099"}}